No. As of September 2026, figures made on BioRender's free plan (BioRender Basic), the 14-day trial, and the Undergrad plan cannot be used in a journal article, a published thesis, a textbook chapter, or any commercial material. BioRender's own pricing FAQ says it in one sentence, and free exports also carry a permanent watermark. What the free plan does cover is real and generous: unpublished theses, grant applications, academic conference posters, teaching slides, lab meetings, and non-profit personal blogs. The dividing line is not "academic versus commercial" — it is published versus unpublished. Three details catch people late: publication rights attach at export time rather than payment time, Individual-plan users must hold a first, co-first, co-senior, or last author position, and open-access journals require a CC BY 4.0 flavour of the license. Here are the exact rules, the failure modes, and what clearing them costs.
The short answer depends on four situations, not one
BioRender's help centre reduces the whole question to a four-row table, and it is worth memorising because every edge case falls out of it:
| Your situation | Can you publish? |
|---|---|
| On a Premium plan, exported while the subscription was active | Yes |
| Exported on a Premium plan, then downgraded | Yes |
| Downgraded before exporting | No |
| On the free plan, free trial, or Undergrad plan | No |
Row three is the one that costs people a resubmission. Publication rights are attached to the exported file, not to your account history and not to your receipt. A figure you built during a paid month but exported after cancelling is not licensed. Conversely, a figure you exported during a paid month stays licensed forever, even if you never pay BioRender again. If you are about to let a subscription lapse, export everything first — including the figures you think are finished, because a re-export after downgrading will not carry rights.
What the free plan actually allows in 2026
BioRender publishes a use-case grid, and the free column is not empty. Permitted on Basic and the trial:
- Unpublished theses and dissertations, including copies uploaded to a university library or institutional repository
- Grant applications
- Academic conference posters and conference presentations to academic audiences
- Teaching slides, assignments, and exams
- Internal lab or team meetings
- Personal YouTube, social media, and personal blog posts that generate no profit
Not permitted on Basic or the trial:
- Journal publication and journal covers
- Published theses distributed beyond your institution
- Not-for-profit or for-profit textbook figures
- Any commercial or revenue-generating use, including a company website or marketing material
- Print use of any kind — BioRender states that a Premium plan is required for all print users
There is also a hard constraint before you get to licensing at all: the free academic plan caps you at 3 figures and 1 graphing file, and every export is watermarked. For a first-year student sketching a lab meeting slide, that is fine. For anyone assembling a five-panel manuscript, it stops being a licensing question and becomes a capacity one.
Three gotchas that catch people after acceptance
The author-position rule on Individual plans
This is the least-known clause and the most disruptive. If you hold an Academic Individual, Student, Postdoc, or Industry Individual plan, you may only publish a BioRender figure in a paper where you are listed as first, co-first, co-senior, or last author. Make a beautiful pathway diagram for a colleague's paper where you land as third author, and your Individual subscription does not cover it — even though you paid, exported correctly, and cited properly.
Lab, Institutional, Team, and Enterprise plans remove the restriction entirely: any author position, any collaboration, no listing required. So the practical rule for a service-minded postdoc who draws figures for the whole group is that the Individual plan is the wrong product, regardless of price.
Open access needs a different license than closed access
At export you choose "Yes" for open-access or "No" for closed-access, and the choice determines the license you receive. Selecting "Yes" issues a combined CC BY 4.0 publication license. That matters downstream: under CC BY, anyone may reuse and adapt your figure provided they credit you, link the license, and flag modifications — and BioRender's guidance is explicit that changing colours, cropping, or removing an icon all count as adaptations requiring an "adapted from" statement. You can regenerate the license with different settings later, but you cannot un-publish a CC BY figure once it is out.
Editing outside BioRender does not release you
A common assumption is that once a figure is opened in Illustrator or PowerPoint and reworked, it becomes "yours." It does not. BioRender requires a publication license for the icons regardless of where the final assembly happened, and the documented workflow is to upload your externally edited figure back into BioRender and export the license from there. Citation is still mandatory, in the form Figure(s) partially created in BioRender. Last Name, First Initial. (Year) [figure URL]. Any tool that hands you icons under a per-figure license behaves this way; the point is simply that "I edited it elsewhere" is not the escape hatch people assume.
What clearing the licensing bar costs, as of September 2026
The honest comparison is not free-versus-free. It is "what does the cheapest plan that lets me publish cost, and what do I get in the export."
| BioRender Free (Basic) | BioRender Academic Individual | FigPad Plus | |
|---|---|---|---|
| Price | $0 | $35/mo billed annually, $39 month-to-month | $15/mo billed annually, $25 month-to-month |
| Journal publication rights | No | Yes | Yes, on any paid plan |
| Author-position restriction | n/a | First, co-first, co-senior, or last author | None stated |
| Watermark on export | Yes | No | No on paid plans |
| Figure count | 3 figures, 1 graphing file | Unlimited | Credit-based |
| Vector export | No | PPTX export of editable images | Layered SVG (Plus/Pro) plus PPTX |
| Icon library | Large, curated, field-specific | Large, curated, field-specific | No comparable curated library |
| AI figure generation | Free credits for AI tools | Paid add-on, from $5/mo annually | Core workflow |
| Mandatory citation of the tool | n/a | Yes, unique license URL required | Not required |
All figures verified against the vendors' public pricing and help pages on 10 September 2026. Prices may change; we re-check monthly.
Two things in that table deserve emphasis. First, BioRender's icon library is genuinely excellent and is not something a generative tool replicates — that is a real reason to pay them. Second, note that AI figure generation moved to a paid add-on on top of the subscription, starting at $5/month on annual academic billing (and $25/month on industry), which changes the "BioRender does AI too" calculus for anyone budgeting a year ahead.
What to do if you already submitted a free-plan figure
If the figure was made on Basic or the trial and the manuscript is under review, you are not in trouble yet. Publication licenses are generally requested after acceptance, not at submission. The recovery path:
- Upgrade to a Premium plan.
- Re-open the figure and re-export it while the subscription is active — the export is what carries the rights.
- Generate the publication license, choosing open-access or closed-access to match the journal.
- Add the unique citation and URL to the figure legend, references, or acknowledgements, per the journal's preference.
- Keep the license PDF. If you already returned proofs without the citation, ask the editorial office whether it can go in at the proof or revision stage.
If your only barrier is the author-position rule — you are a middle author on an Individual plan — upgrading yourself does not fix it. Either the corresponding author exports the figure under their own eligible plan, or the group moves to a Lab plan.
How FigPad fits
FigPad exists for the part of this that licensing rules cannot solve: the revision. When a reviewer asks you to rename a label, split a panel, or recolour one arrow, a flat PNG means redrawing. FigPad generates from a prompt, a sketch, or a reference image and exports layered SVG — text stays text, arrows stay arrows, not a welded outline — plus PPTX where the graphic lands in the slide as editable objects. It also runs the reverse direction: a raster figure can be vectorised back into editable shapes, and a PDF manuscript can be turned into a conference poster (up to 80MB, parsing the first 30 pages).
On licensing, our position is deliberately boring. Every paid tier carries publication rights. There is no separate "publishing" tier, no per-figure charge, no author-position clause, and no mandatory citation of the tool; the terms state that you own the outputs generated for you. Pricing runs $9–31/month billed annually ($19–39 month-to-month) as of September 2026, and new accounts get free credits with no card required — those signup credits are for evaluation, so publication rights begin at the first paid tier. Credits are cheap enough that revision is not a budgeting decision: a generation costs 2 credits, a text fix 2, editing elements on the canvas is free, and an editable SVG export is 4 credits with re-exports of the same version free — a typical generate–revise–export loop lands around 16 credits.
If you are comparing head to head, the BioRender alternative breakdown covers where each tool wins. If your immediate job is a submission graphic, start at the graphical abstract generator or the AI scientific figure generator, and the pricing page lists what each tier includes.
When you should stay with BioRender
Be clear-eyed about this. Stay on BioRender if:
- Your field lives in its icon library. Immunology, virology, molecular and cell biology diagrams built from curated, scientifically vetted icons are BioRender's core strength, and matching a lab's existing visual conventions is worth real money.
- Your institution already pays. An Institutional or Lab license removes the author-position rule, the cost question, and the licensing question in one move. Check with your library before paying out of pocket — many universities have site licenses that researchers never hear about.
- Reviewers and co-authors expect the house style. If your last four papers used BioRender figures, visual consistency across a body of work is a legitimate reason not to switch mid-project.
- You need in-app co-editing with a large team. Shared folders, real-time co-editing, and brand kits are mature there.
- You already exported everything under an active subscription. Those files are licensed permanently. Nothing forces you to migrate them.
The case for switching is narrower and more specific: cost per finished figure, and how much a reviewer's label change costs you in time.
Key Takeaways
- Free plan figures cannot be published. Journals, published theses, textbooks, print, and any commercial use all require a paid Premium plan; the free plan covers unpublished theses, posters, grants, and teaching.
- Rights attach at export, not at payment. Export before you downgrade, and re-export any figure you edited after a lapse.
- Individual plans carry an author-position rule. First, co-first, co-senior, or last author only — middle authors need a Lab, Institutional, Team, or Enterprise license.
- Open access means CC BY 4.0. Choose the right license type at export; adaptations by others require an "adapted from" credit.
- Editing in Illustrator or PowerPoint changes nothing. Upload the final figure back, export the license, and cite it.
